Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…
Browsing: Inotuzumab
Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment…
Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell…
Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the…
Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer…
Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock,…
In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing…
Shira N. Dinner, MD. Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Sherra Diner, MD, an esteemed associate…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…